Skip to main content Skip to navigation

FOI/25/020

Read more about this page below
Reference FOI/25/020
Description Biliary Tract and Non-Small Cell Lung Cancer Treatment
Date requested 11/04/2024
Attachments N/A

Request

I would be grateful if you could please provide the following information with regards to patients treated with Durvalumab (Imfinzi) and Nivolumab.

Where the specified Nov 23 – March 24 timeframe is not possible to provide, could you please provide the latest 5 months of data you have, and specify which timeframe this covers.

  1. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Durvalumab for the following indications?
    A) Biliary Tract Cancer
    B) Non-Small Cell Lung Cancer
     
  2. How many unique total patients were treated in the last 5 months (Nov 23 – March 24) with Nivolumab for early stage (resectable) non-small cell lung cancer (Stages 1 – 3b).
     
  3. How may unique total patients were treated last month (March 24) with Durvalumab for the following indications?
    C) Biliary Tract Cancer
    D) Non-Small Cell Lung Cancer
     

Response

Having completed enquiries within the Trust, CLCH does not hold information relating to your request. CLCH confirm we do not provide therapeutic cancer treatment within the Trust.

Return to FOI Requests